Hematological Agents : Hematopoietic Agents
IMIRC1 “Mircera pre-filled syringe injection” 100 mcg/0.3 ml inj/pre-filled syringe
IRECO7 “Recormon pre-filled syringe injection” 5000 IU/ml; 1 ml/syringe
適應症：
IMIRC1：治療慢性腎病所引起的症狀性貧血。Mircera尚未核准於治療因癌症化學療法引起的貧血。
IRECO7：治療慢性腎衰竭且伴隨症狀性貧血病人。治療與癌症化學治療有關的症狀性貧血。治療正在接受抗腫瘤治療之多發性骨髓瘤(multiple myeloma)、低度非何杰金氏淋巴瘤(low grade non-Hodgkin’s lymphoma)或慢性淋巴性白血病(chronic lymphocytic leukemia)成人患者的症狀性貧血。
Usual dose:
Anemia associated with Prematurity, ESRD: slow IV/SC
Adult: 2000 IU 2-3 times/wk.
Pediatric
(children): 50-100 IU 3 times/wk.
(neonates): 100-500 IU/kg q1-2day for 10-21 days.
Adverse effect:
Common: arthralgias, clotted access, headache.
健保使用規範：見darbepoetin Alfa。
Related Entries
(Visited 43 times, 1 visits today)